Palogic Value Management L.P. Acquires New Stake in Health Catalyst, Inc. (NASDAQ:HCAT)

Palogic Value Management L.P. bought a new stake in Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 320,000 shares of the company's stock, valued at approximately $2,262,000. Palogic Value Management L.P. owned approximately 0.46% of Health Catalyst as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Group One Trading LLC grew its holdings in shares of Health Catalyst by 107.6% in the fourth quarter. Group One Trading LLC now owns 4,360 shares of the company's stock valued at $31,000 after purchasing an additional 2,260 shares in the last quarter. Two Sigma Securities LLC boosted its stake in Health Catalyst by 19.5% during the fourth quarter. Two Sigma Securities LLC now owns 17,510 shares of the company's stock worth $124,000 after buying an additional 2,862 shares during the period. Legato Capital Management LLC boosted its stake in Health Catalyst by 3.7% during the fourth quarter. Legato Capital Management LLC now owns 87,992 shares of the company's stock worth $622,000 after buying an additional 3,171 shares during the period. Quantbot Technologies LP purchased a new position in Health Catalyst during the fourth quarter worth $29,000. Finally, Price T Rowe Associates Inc. MD boosted its stake in Health Catalyst by 8.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 62,443 shares of the company's stock worth $442,000 after buying an additional 4,798 shares during the period. 85.00% of the stock is owned by hedge funds and other institutional investors.

Health Catalyst Stock Up 1.1%

Shares of HCAT stock traded up $0.04 on Friday, hitting $3.78. The stock had a trading volume of 565,285 shares, compared to its average volume of 595,492. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. The business has a 50 day moving average price of $4.00 and a 200 day moving average price of $5.47. The company has a market cap of $263.09 million, a PE ratio of -2.80 and a beta of 1.56. Health Catalyst, Inc. has a one year low of $3.49 and a one year high of $9.24.

Wall Street Analysts Forecast Growth

Several research analysts have commented on HCAT shares. KeyCorp dropped their price objective on shares of Health Catalyst from $7.00 to $5.00 and set an "overweight" rating for the company in a research note on Wednesday, April 16th. Stephens dropped their price objective on shares of Health Catalyst from $7.00 to $5.00 and set an "equal weight" rating for the company in a research note on Thursday, March 6th. Citigroup dropped their price objective on shares of Health Catalyst from $7.00 to $6.50 and set a "buy" rating for the company in a research note on Friday, April 25th. Evercore ISI lowered shares of Health Catalyst from an "outperform" rating to an "inline" rating in a research note on Wednesday, April 9th. Finally, Royal Bank of Canada decreased their target price on Health Catalyst from $7.00 to $6.00 and set a "sector perform" rating for the company in a research report on Thursday, February 27th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $8.00.

Insider Activity at Health Catalyst

In other news, COO Daniel Lesueur sold 16,902 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $4.52, for a total transaction of $76,397.04. Following the completion of the transaction, the chief operating officer now directly owns 216,250 shares of the company's stock, valued at $977,450. This represents a 7.25% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, General Counsel Benjamin Landry sold 13,827 shares of the company's stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $4.55, for a total value of $62,912.85. Following the transaction, the general counsel now directly owns 160,437 shares of the company's stock, valued at approximately $729,988.35. The trade was a 7.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 41,147 shares of company stock worth $182,284 over the last quarter. Insiders own 2.50% of the company's stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.